Max Robotics — Global Service Robot Directory + US Certification

About

Lars A. Akslen is a leading figure in translational cancer research, with a focus on tumor microenvironment interactions, epithelial plasticity, and drug resistance mechanisms. His work has fundamentally advanced our understanding of how cancer cells adapt to evade therapy. In a highly cited 2018 study (25 citations), Akslen demonstrated that specific microenvironments can induce non-sporadic expression of AXL and cKIT receptors, linking these changes to epithelial plasticity and acquired drug tolerance—a critical insight for overcoming therapy failure. He has also made significant contributions to precision oncology, as shown in his 2017 work (22 citations) that improved preoperative risk stratification for prostate cancer by integrating multiparametric MRI features into established tools like CAPRA and D'Amico, enhancing treatment planning for over 800 patients. With a career spanning decades, Akslen’s research has been cited thousands of times, reflecting its profound impact on both basic cancer biology and clinical practice. His work continues to shape strategies for personalized cancer therapy and resistance management.